Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Operating Leases (2022 - 2025)

Oncology Institute's Operating Leases history spans 4 years, with the latest figure at $19.1 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 17.62% year-over-year to $19.1 million; the TTM value through Dec 2025 reached $19.1 million, down 17.62%, while the annual FY2025 figure was $19.1 million, 17.62% down from the prior year.
  • Operating Leases reached $19.1 million in Q4 2025 per TOI's latest filing, down from $20.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $32.1 million in Q3 2023 to a low of $18.7 million in Q1 2022.
  • Average Operating Leases over 4 years is $25.1 million, with a median of $24.9 million recorded in 2023.
  • Peak YoY movement for Operating Leases: skyrocketed 49.26% in 2023, then tumbled 35.71% in 2025.
  • A 4-year view of Operating Leases shows it stood at $22.1 million in 2022, then increased by 20.06% to $26.5 million in 2023, then fell by 12.32% to $23.2 million in 2024, then fell by 17.62% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Operating Leases are $19.1 million (Q4 2025), $20.2 million (Q3 2025), and $28.1 million (Q2 2025).